论文部分内容阅读
为探讨低危骨髓增生异常综合征（ＭＤＳ）初诊时实验室检查结果与其预后及转归的关系，对９６例低危ＭＤＳ随访观察１２～５５个月。转为ＲＡＥＢ或ＲＡＥＢ－ｔ１０例，转为白血病１６例。死亡２７例，其中１５例死于骨髓衰竭，１２例死于白血病。初诊时外周血血红蛋白＜４０ｇ／Ｌ，血小板＜２０×１０９／Ｌ，中性粒细胞＜０５×１０９／Ｌ，骨髓涂片粒系增生活跃者预后不良；骨髓活检红系增生占优者转白率、病死率低于粒系增生占优者，骨髓造血细胞增生低下者易死于骨髓衰竭，ＡＬＩＰ阳性者转白率及病死率明显高于阴性者。单因素分析结果提示：初诊时实验室检查结果有助于判断低危ＭＤＳ的转归及预后
To explore the relationship between laboratory findings, prognosis, and prognosis of low-risk myelodysplastic syndrome (MDS) at the time of initial diagnosis, 96 low-risk MDS were followed up for 12 to 55 months. Turn to RAEB or RAEB-t10 cases and turn to leukemia in 16 cases. Of the 27 deaths, 15 died of bone marrow failure and 12 died of leukemia. At the initial diagnosis, peripheral blood hemoglobin <40g/L, platelets <20x109/L, neutrophils <0x5x109/L, bone marrow smear granulocytic hyperplasia have a poor prognosis; bone marrow biopsy erythroid hyperplasia predominates The conversion rate and mortality were lower than those with granulocyte hyperplasia. Those with low bone marrow hematopoietic progenitors could easily die of bone marrow failure, and the ALIP-positive patients had a significantly higher conversion rate and mortality than those with negative results. Univariate analysis results suggest that the results of laboratory tests at the time of initial diagnosis will help determine the prognosis and prognosis of low-risk MDS.